Global X SuperDividend ETF vs Twist Bioscience Corp — how do they compare? Global X SuperDividend ETF trades at $23.75 (market cap $1.17B), while Twist Bioscience Corp trades at $158 (market cap $10.32B). The key difference: Twist Bioscience Corp is far larger — about 8.8× Global X SuperDividend ETF's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Global X SuperDividend ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X SuperDividend ETF for 47 Days and Twist Bioscience Corp for 27 Days on average.
| SDIV | TWST | |
|---|---|---|
Market Cap | $1.17B | $10.32B |
Volume | 432,039 | 5,894,998 |
Sector | Broad Market / Factor | Health |
52-Week High | $26.34 | $205.00 |
52-Week Low | $22.90 | $25.45 |
Typical Hold Time | 47 Days | 27 Days |
Enterprise Value | — | $10.24B |
Signals from Pluang's Aura AI — not financial advice
SDIV trades at $23.58, down 0.55% with a bearish technical signal from moving averages. The ETF maintains an 8%+ dividend yield but faces scrutiny over principal erosion, having lost 66% since inception. Recent institutional buying by Ameritas Advisory contrasts with negative media coverage questioning sustainability of high yields amid capital depreciation.
Outlook remains challenged by structural underperformance versus benchmarks. The high yield attracts income seekers but masks negative growth and volatility risks. Investment case hinges on yield sustainability versus capital preservation, with analyst sentiment cautious given persistent track record of value destruction.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →